Sumitomo Pharma America, Inc.
Enzomenib
Leukemia, Myeloid, Acute
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for Enzomenib in Leukemia, Myeloid, Acute are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT04988555: Phase 2 trial, sponsor Sumitomo Pharma America, Inc., drug Enzomenib. Primary completion date 2027-06-30 (estimated).”